The company is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eye care practitioners and patients around the world.

The company has two products under development, NCX 470 for glaucoma and NCX 4751 for blepharitis. The glaucoma drug is to be launched in 2024 and sales of over €450 million are projected in the United States and other major markets. NCX 470 targets the $1.4 Billion U.S. glaucoma PGA market.

• Capital raise: £10 million GBP
• Headquarters: Paris, France
• Type of entity: Publicly traded company
• Use of proceeds: Securing FDA approval for
  NCX 470 and NCX 4751 in the United States.
• USPs: Well established company, very large
  target market, highly experienced team.
• Type of investment: Equity
• Geography: Europe/ US
• Annual revenue: €14.4m EUR
• Min. ticket size: £500K GB